|Bid||0.00 x 1400|
|Ask||0.00 x 800|
|Day's Range||104.72 - 106.13|
|52 Week Range||73.69 - 106.38|
|PE Ratio (TTM)||N/A|
|Earnings Date||Oct 23, 2018|
|Forward Dividend & Yield||2.25 (2.13%)|
|1y Target Est||97.13|
Trade or fade the week's big winners? The Fast Money traders weigh in. With CNBC's Melissa Lee and the Fast Money traders, Brian Kelly, Gina Sanchez, David Seaburg and Dan Nathan.
Merck (MRK) gets FDA approval to include overall survival data from a key late-stage lung cancer study, KEYNOTE-189 study, on the label of its PD-L1 inhibitor, Keytruda.
On August 17, Teva Pharmaceutical Industries (TEVA) was trading at a forward PE (price-to-earnings) ratio of 8.5x, compared to the industry average PE of 12.1x. The company’s forward EV-to-EBITDA1, which is a capital structure–neutral valuation measure, is 10.8x. A stock’s forward PE ratio is calculated by dividing its current stock price by the next-12-month earnings estimate of the company.
Allergan (AGN) is developing a variety of products through internal programs as well as in collaboration with other companies. A few of the products it currently has under development are Cenicriviroc, Atogepant, Bimatoprost SR, Ubrogepant, Abicipar, Rapastinel, and Sarecycline.
Amgen’s (AMGN) product portfolio includes the blockbuster drugs Prolia, Enbrel, Neulasta, Xgeva, Aranesp, Sensipar/Mimpara, Kyprolis, and Epogen. Blockbuster drug Neulasta (pegfilgrastim) reported a 1% rise in revenue to $1.10 billion during the second quarter compared to ~$1.09 billion in the second quarter of 2017.
Major pharmaceutical companies are partying like it’s 2001. U.S. drugmakers including Pfizer Inc., Eli Lilly & Co., and Merck & Co. are seeing their share prices balloon to the highest levels in more than 16 years as investors rotate in after second-quarter results proved stronger than expected. Impressive earnings paired with waning concerns about potential Trump administration actions on drug pricing could be helping to draw generalist investors in a bit of a “catch up trade,” according to Credit Suisse analyst Vamil Divan.
Allergan’s (AGN) US General Medicines segment includes women’s health products, central nervous system products, anti-infective products, gastrointestinal products, and diversified brands.
On August 16, Teva announced positive top-line data for its NGF-inhibitor Fasinumab, which is being developed in collaboration with Regeneron. Teva’s stock price rise was also boosted by the FDA approval of Teva’s generic version of EpiPen, which we covered in FDA Approves Teva’s Generic Version of EpiPen, Stock Up 7.5%. Teva also has Fremanezumab in its product pipeline, which is expected to be a key growth driver for the company and is being developed for the treatment of migraines.
Lilly (LLY) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on Aug. 16) Autolus Therapeutics Ltd – ADR (NASDAQ: AUTL ) Eli Lilly And ...
Eli Lilly and Co.'s ( LLY) stock has jumped by more than 16% since the middle of July and by nearly 24% in 2018. The stock is poised to plunge 15% in the coming weeks, based on technical analysis. Eli Lilly's stock broke out following better-than-expected quarterly results and guidance, rising above a long-term technical resistance level around $88.50.
Bausch Health Companies’ (BHC) wholly-owned subsidiary Ortho Dermatologics generated revenue of $142.0 million in the second quarter compared to $162 million in the second quarter of 2017, reflecting a ~12% YoY (year-over-year) fall.
Karuna Pharmaceuticals Inc., which is developing treatments for schizophrenia and other neurological conditions, has appointed Chairman Steven Paul as chief executive.
Under its immunology program, Nektar Therapeutics (NKTR) is developing NKTR-358 in collaboration with Eli Lilly and Company (LLY).
Elanco will place the net proceeds of the Offering into escrow, to be released upon either the completion of its previously announced, anticipated initial public offering (IPO) or a special mandatory redemption, which would occur if the IPO does not take place, or Lilly otherwise determines that the IPO will not take place, by June 30, 2019. Elanco intends to pay the net proceeds of the Offering as part of the consideration to Lilly.
Nektar Therapeutics (NKTR) generated revenue of $1.09 billion in the second quarter compared to $34.59 million in the second quarter of 2017.
In its Q2 2018 earnings conference call, Pfizer (PFE) updated its fiscal 2018 revenue guidance from the previously projected range of $53.5 billion–$55.5 billion to $53.0 billion–$55.0 billion, mainly to account for the unfavorable foreign currency fluctuations from mid-April 2018 to mid-July 2018. Analysts have projected Pfizer’s fiscal 2018 revenues to come in around $54.2 billion, which would be a year-over-year (or YoY) rise of approximately 3.1%. Merck (MRK), Eli Lilly (LLY), and Novartis (NVS) are expected to report revenues close to $42.4 billion, $24.3 billion, and $52.4 billion, respectively, in fiscal 2018.
In the first half of 2018, Novo Nordisk’s fast-acting insulins segment generated revenues of 9.7 billion Danish kroner, reflecting a ~2% YoY (year-over-year) growth in local currencies.
Today, Mylan Pharmaceuticals (MYL) announced the launch of tadalafil tablets USP (20 mg) in the United States. The drug is the first generic version of Eli Lilly’s (LLY) Adcirca (tadalafil) approved by the FDA.
Novo Nordisk’s (NVO) Victoza generated revenues of 11.7 billion Danish kroner in the first half of 2018 compared to 11.5 billion Danish kroner in the first half of 2017, a ~2% YoY (year-over-year) growth and a ~12% YoY growth in local currencies.
Novo Nordisk (NVO) reported net revenues of 54.3 billion Danish kroner in the first half of 2018 compared to 57.1 billion Danish kroner in H1 2017. That’s a ~5% YoY (year-over-year) decline.
Analysts expect Pfizer’s (PFE) adjusted EPS to be $2.99 on revenue of $54.3 billion in 2018, a 3.4% rise compared to $52.5 billion in 2017. Analysts also expect a 10.9% rise in the company’s adjusted net income during 2018, mainly due to a fall in its selling, general, and administrative expenses as well as its lower research and development expenses as a percentage of its sales.